Equities

Oxford Nanopore Technologies PLC

ONT:LSE

Oxford Nanopore Technologies PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)141.00
  • Today's Change-5.20 / -3.56%
  • Shares traded1.21m
  • 1 Year change5.22%
  • Beta1.1554
Data delayed at least 20 minutes, as of Feb 06 2026 16:43 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Oxford Nanopore Technologies PLC grew revenues 7.97% from 169.67m to 183.19m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -154.51m to -146.19m.
Gross margin57.32%
Net profit margin-70.02%
Operating margin-75.08%
Return on assets-20.56%
Return on equity-26.01%
Return on investment-24.11%
More ▼

Cash flow in GBPView more

In 2024, cash reserves at Oxford Nanopore Technologies PLC fell by 21.02m. Cash Flow from Financing totalled 73.58m or 40.17% of revenues. In addition the company used 109.89m for operations while cash from investing totalled 15.03m.
Cash flow per share-0.1024
Price/Cash flow per share--
Book value per share0.5446
Tangible book value per share0.491
More ▼

Balance sheet in GBPView more

Oxford Nanopore Technologies PLC appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.79
Quick ratio3.89
Total debt/total equity0.0843
Total debt/total capital0.0777
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.